Results 201 to 210 of about 156,095 (350)

The Impact of Chronic Particulate Matter Exposure on Quality‐of‐Life Outcomes After Endoscopic Sinus Surgery

open access: yes
International Forum of Allergy &Rhinology, EarlyView.
Chandler Rygalski   +10 more
wiley   +1 more source

Estimation and rapid identification of later stages during embryonic development of the oviparous lizard Sceloporus aeneus (Squamata: Phrynosomatidae)

open access: yesThe Anatomical Record, EarlyView.
Abstract Stages of embryonic development for reptiles have been presented in tables that may include all or part of embryonic development. When oviposition occurs in some lizards, embryos are already in the later stages of development; likewise, the size of the eggs increases as incubation time progresses.
Nivia Rocio Antonio‐Rubio   +3 more
wiley   +1 more source

A contribution to the anatomy of two rare cetacean species: The hourglass dolphin (Cephalorhynchus cruciger) and the spectacled porpoise (Phocoena dioptrica)

open access: yesThe Anatomical Record, EarlyView.
Abstract The anatomical description of the hourglass dolphin (Cephalorhynchus cruciger) and the spectacled porpoise (Phocoena dioptrica) remains largely unexplored, due to limited specimen availability and preservation challenges. This study employed digital imaging techniques, conventional histology, and computed tomography to provide visualization of
Jean‐Marie Graïc   +26 more
wiley   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Home - About - Disclaimer - Privacy